Olema Pharmaceuticals (OLMA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on the stock and has a $28.00 price target.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Emily Bodnar’s rating is based on the promising results from Olema Pharmaceuticals’ recent clinical trials, particularly the VERITAC-2 trial. The trial demonstrated significant efficacy in patients with ESR1 mutations, showing improved progression-free survival (PFS) compared to existing treatments. This positive outcome highlights the potential of Olema’s therapeutic approach in addressing unmet needs in metastatic breast cancer treatment.
Furthermore, the safety profile of the treatment was favorable, with no major increases in adverse events, which supports its potential for broader clinical application. The combination of these factors suggests a strong growth potential for Olema Pharmaceuticals, justifying the Buy rating assigned by Emily Bodnar.
In another report released today, Oppenheimer also reiterated a Buy rating on the stock with a $22.00 price target.